Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | HRH1 | P35367 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12694263 | 1.00 | RAB9A (0.41) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10115951 | 1.00 | RAB9A (0.41) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13104826 | 1.00 | RAB9A (0.41) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28822429 | 0.84 | KDM4E (0.40) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18595067 | 0.83 | SMN1; SMN2 (0.37) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL295095 | 0.81 | KDM4E (0.38) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26828373 | 0.80 | CYP2D6 (0.39) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL8507646 | 0.80 | ATM (0.37) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12041542 | 0.79 | KDM4E (0.37) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL30719393 | 0.79 | KDM4E (0.39) | RAB9AALDH1A1SMN1; SMN2KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| EP-3875151-B1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023125182-A1 | PROPIONIC ACID DERIVATIVE AND MEDICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023081637-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190329292-A1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20100248143-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, AND PATTERN-FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-1490371-B1 | THIOPHENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1513412-B1 | COFFEE AROMA HAVING AN IMPROVED STABILITY | SYMRISE GMBH & CO KG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-6579553-B1 | Reaction product cysteine, hydrogen sulfide, ammonium sulfide and extracellular liquid fusarium extracts used as food flavors | ZENECA LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-6540691-B1 | Determining the presence or absence of aging in a mammal by analyzing samples of breath and air to determine content of n-alkanes, find differences in the alkane profile from the baseline alkane profile indicate aging | PHILLIPS MICHAEL (US) | 2003-04-01 | — | — | US | disclosed |
| US-6221026-B1 | Breath test for the detection of various diseases | PHILLIPS MICHAEL (US) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | RAB9A 3873/4885KMT2A 1334/4885ALDH1A1 402/4885 |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | RAB9A 2612/4885KMT2A 3989/4885ALDH1A1 4447/4885 |
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | RAB9A 3873/4885KMT2A 1334/4885ALDH1A1 402/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | RAB9A 1042/4885KMT2A 2988/4885ALDH1A1 2185/4885 |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | RAB9A 2964/4885KMT2A 1070/4885ALDH1A1 170/4885 |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | RAB9A 1826/4885KMT2A 1858/4885ALDH1A1 623/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | RAB9A 3422/4885KMT2A 2749/4885ALDH1A1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.